In murine models of colon, skin and brain cancer, however, host IDO1 deficiency does not diminish tumor growth (321–323), although it modestly enhances the efficacy of immune checkpoint blockade therapies (322) or decreases regulatory T-cell infiltration (323). The gene discussed is IDO1; the disease is neoplasm.